TuHURA Biosciences Reports FY2025 Results, Quantifies Short Cash Runway, and Details Clinical Milestones

summarizeSummary

TuHURA Biosciences reported its FY2025 financial results, revealing a short cash runway of approximately 1.6 quarters, while also detailing significant clinical progress and upcoming milestones for its oncology pipeline.

check_boxKey Events

• Quantified Short Cash Runway

  The company reported $3.6 million in cash and equivalents at December 31, 2025, with an additional $7.5 million received in Q1 2026, totaling $11.1 million. With an operating cash outflow of $27.7 million for 2025, this indicates a very short cash runway of approximately 1.6 quarters, confirming the going concern warning from the recent 10-K.

• Significant Clinical Progress

  TuHURA Biosciences continues to enroll patients in its Phase 3 study for IFx-2.0 in Merkel Cell Carcinoma, with enrollment anticipated to complete in mid-2027. The company also initiated a Phase 1b/2a study for IFx-2.0 in Merkel Cell Carcinoma of Unknown Primary Origin.

• Key Upcoming Milestones Detailed

  The company outlined several anticipated milestones, including Orphan Drug Designation for IFx-2.0 (1H 2026), preliminary Phase 1b/2a data (2H 2026), an FDA meeting for TBS-2025 (June 2026), and initiation of a Phase 1b/2 trial for TBS-2025 (2H 2026).

• Increased Operating Expenses

  Research and development expenses increased to $20.5 million in 2025 from $13.3 million in 2024, and general and administrative expenses rose to $7.6 million from $3.9 million over the same period, reflecting increased operational activity.

auto_awesomeAnalysis

This 8-K filing, following yesterday's 10-K with a going concern warning, provides the detailed financial results for fiscal year 2025 and a comprehensive corporate update. The company reported cash and equivalents of $3.6 million at year-end 2025, supplemented by an additional $7.5 million in Q1 2026 from prior offerings, bringing total available cash to $11.1 million. With an operating cash outflow of $27.7 million for 2025, the company faces a very short cash runway, underscoring the urgency for further financing. Despite the financial challenges, TuHURA Biosciences highlighted significant clinical progress, including ongoing Phase 3 enrollment for IFx-2.0 in Merkel Cell Carcinoma and a robust pipeline of upcoming milestones for its IFx-2.0, TBS-2025, and ADC programs throughout 2026 and 2027. Investors should monitor the company's ability to secure additional capital to fund its clinical development.